# A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants

> **NCT07463196** · PHASE1 · RECRUITING · sponsor: **AC Immune SA** · enrollment: 78 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Placebo
- **DRUG:** ACI-19764 at dose A1
- **DRUG:** ACI-19764 at dose A2
- **DRUG:** ACI-19764 at dose A3
- **DRUG:** ACI-19764 at dose A4
- **DRUG:** ACI-19764 at dose A5
- **DRUG:** ACI-19764 at dose A6
- **DRUG:** ACI-19764 at dose B1
- **DRUG:** ACI-19764 at dose B2
- **DRUG:** ACI-19764 at dose B3

## Key facts

- **NCT ID:** NCT07463196
- **Lead sponsor:** AC Immune SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-28
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07463196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07463196, "A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07463196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*